JMP reiterates Sangamo at market outperform

Sangamo BioSciences, Inc. was reiterated by JMP Securities analyst Charles C. Duncan at a market outperform rating and an $8 price target after preclinical data showed its anti-HIV compound potentially offers viral protection. The data was presented at a recent medical conference. The study confirms that disruption of the CCR5 gene is a valid approach in HIV treatment. Shares of the Richmond, Calif., biopharmaceutical company were down $0.157, or 3.67%, at $4.103 on volume of 163,770 shares versus the three-month running average of 67,136.9 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.